Clinicopathological Features and Molecular Typing of Invasive Fibroma of Abdominal Wall
Launched by SHANDONG PROVINCIAL HOSPITAL · Jan 11, 2024
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called aggressive fibromatosis of the abdominal wall, which is a type of tumor that can grow in the body's soft tissues. The goal of the study is to better understand the characteristics of this tumor, the factors that might make it come back after surgery, and how surgery affects patients' quality of life. Researchers will analyze data from multiple hospitals and look at tissue samples from previous surgeries to gather this information.
To be eligible for the trial, participants must have had surgery for invasive fibroma of the abdominal wall and have complete clinical information available. They also need to agree to be part of the study. Unfortunately, individuals who cannot cooperate with the research or who have cognitive difficulties will not be able to participate. Participants can expect to contribute to important research that may help improve treatment and care for future patients with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ① Surgical treatment for "invasive fibroma of abdominal wall"; ② Complete clinical data; ③ Agree to participate in the project.
- Exclusion Criteria:
- • ① can not cooperate with the project implementation; ② There is cognitive dysfunction; Refuse to participate in research projects.
About Shandong Provincial Hospital
Shandong Provincial Hospital is a leading medical institution located in Jinan, China, renowned for its commitment to advancing healthcare through innovative clinical research. As a prominent sponsor of clinical trials, the hospital focuses on enhancing patient care and therapeutic outcomes across various medical disciplines. With a multidisciplinary team of experienced healthcare professionals and researchers, Shandong Provincial Hospital emphasizes rigorous scientific methodology, ethical standards, and patient safety in its clinical research initiatives. The hospital's state-of-the-art facilities and collaborative environment foster the development of groundbreaking treatments, ultimately contributing to the global medical community's knowledge and practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Trial Officials
Yulong Shi, MD
Study Chair
Shandong Provincial Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported